A study from the Intermountain Medical Center Heart Institute has shocking findings about certain blood pressure medications and mortality outcomes.
Alpha blockers and alpha 2 agonist, two types of blood pressure drugs, are linked to increased variability but not cardiovascular events in blood pressure measurements between physician visits, which is associated with an increased risk of death, according to new research.
Clements
Prior research has shown that patients with large variances in blood pressure between physician visits are at an increased risk of death. The systolic blood pressure reading (the upper number) indicates how much pressure blood is exerting against the artery walls when the heart beats. According to the American Heart Association, a normal systolic blood pressure is less than 120. Blood pressure above 140 is considered high.
Lead study author Brian Clements, DO, internal medicine physician at the Intermountain Medical Center Heart Institute, and colleagues, wanted to assess the risk of blood pressure variability and its causative effect on cardiovascular events and all-cause mortality. Between January 2007 and December 2011, the researchers studied more than 10,500 patients (with an average age of 71 years) with at least seven recorded blood pressure medications. They tracked the range of variances in blood pressure measurements and the class of blood pressure medication each patient was using.
They found that found that certain classes of blood pressure medications produce more consistent blood pressure and better mortality outcome data such as:
Results of the study were presented in March at the American College of Cardiology Scientific Sessions in Orlando, FL.
“It is important for healthcare clinics to use evidence-based techniques to accurately measure blood pressure. Blood pressure medication adherence is of upmost importance,” says Clements. “Variation in measured blood pressure in an office setting predicts greater mortality than no variation. Adherence to evidence-based medicines reduce this.”
Based on the study, Clements offers three pieces of advice for healthcare executives:
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More